Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use.

Mlakar V, Huezo-Diaz Curtis P, Satyanarayana Uppugunduri CR, Krajinovic M, Ansari M.

Int J Mol Sci. 2016 Sep 8;17(9). pii: E1502. doi: 10.3390/ijms17091502. Review.

2.

Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.

Crona DJ, Ramirez J, Qiao W, de Graan AJ, Ratain MJ, van Schaik RH, Mathijssen RH, Rosner GL, Innocenti F.

Pharmacogenomics J. 2016 Feb;16(1):54-9. doi: 10.1038/tpj.2015.23. Epub 2015 Apr 14.

3.
4.

Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Panczyk M.

World J Gastroenterol. 2014 Aug 7;20(29):9775-827. doi: 10.3748/wjg.v20.i29.9775. Review.

5.

Old drug new use--amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity.

Kong R, Liu T, Zhu X, Ahmad S, Williams AL, Phan AT, Zhao H, Scott JE, Yeh LA, Wong ST.

Clin Cancer Res. 2014 Jul 1;20(13):3521-30. doi: 10.1158/1078-0432.CCR-14-0395. Epub 2014 Apr 29.

6.

Understanding and modulating mammalian-microbial communication for improved human health.

Mani S, Boelsterli UA, Redinbo MR.

Annu Rev Pharmacol Toxicol. 2014;54:559-80. doi: 10.1146/annurev-pharmtox-011613-140007. Epub 2013 Oct 23. Review.

7.

Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.

Swami U, Goel S, Mani S.

Curr Drug Targets. 2013 Jun;14(7):777-97. Review.

8.

Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.

Patnaik A, Papadopoulos KP, Tolcher AW, Beeram M, Urien S, Schaaf LJ, Tahiri S, Bekaii-Saab T, Lokiec FM, Rezaï K, Buchbinder A.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1499-506. doi: 10.1007/s00280-013-2149-2. Epub 2013 Mar 30.

9.

Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians.

Liu X, Cheng D, Kuang Q, Liu G, Xu W.

Pharmacogenomics J. 2014 Apr;14(2):120-9. doi: 10.1038/tpj.2013.10. Epub 2013 Mar 26.

10.

Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.

Lévesque E, Bélanger AS, Harvey M, Couture F, Jonker D, Innocenti F, Cecchin E, Toffoli G, Guillemette C.

J Pharmacol Exp Ther. 2013 Apr;345(1):95-101. doi: 10.1124/jpet.112.202242. Epub 2013 Feb 5.

11.

A perspective on efflux transport proteins in the liver.

Köck K, Brouwer KL.

Clin Pharmacol Ther. 2012 Nov;92(5):599-612. doi: 10.1038/clpt.2012.79. Epub 2012 Sep 5. Review.

12.

Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.

Stein A, Voigt W, Jordan K.

Ther Adv Med Oncol. 2010 Jan;2(1):51-63. doi: 10.1177/1758834009355164.

13.

Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.

Deenen MJ, Cats A, Beijnen JH, Schellens JH.

Oncologist. 2011;16(7):992-1005. doi: 10.1634/theoncologist.2010-0260. Epub 2011 Jun 9. Review.

14.

Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.

Shulman K, Cohen I, Barnett-Griness O, Kuten A, Gruber SB, Lejbkowicz F, Rennert G.

Cancer. 2011 Jul 15;117(14):3156-62. doi: 10.1002/cncr.25735. Epub 2011 Feb 1.

15.

Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia.

van der Bol JM, de Jong FA, van Schaik RH, Sparreboom A, van Fessem MA, van de Geijn FE, van Daele PL, Verweij J, Sleijfer S, Mathijssen RH.

Oncologist. 2010;15(10):1063-72. doi: 10.1634/theoncologist.2010-0033. Epub 2010 Oct 7.

16.

Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Ramírez J, Ratain MJ, Innocenti F.

Future Oncol. 2010 Apr;6(4):563-85. doi: 10.2217/fon.10.17. Review.

17.

Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5).

Tahara H, Yee SW, Urban TJ, Hesselson S, Castro RA, Kawamoto M, Stryke D, Johns SJ, Ferrin TE, Kwok PY, Giacomini KM.

J Pharmacol Exp Ther. 2009 Apr;329(1):262-71. doi: 10.1124/jpet.108.146449. Epub 2009 Jan 13.

Items per page

Supplemental Content

Write to the Help Desk